• HPR224 Utilization of Long-Term Care Before and After the 2015 Dutch National Reform: An Interrupted Time Series Analysis

    Dec 1, 2024, 00:00

  • HPR131 Needs and Challenges of the Payor and Regulatory Community Towards Integrating Obesity Into a Chronic Care Framework

    Dec 1, 2024, 00:00

  • EE729 Clinical and Economic Impact of a Tri-Layer Hybrid Biomaterial vs Synthetic Mesh for Ventral Hernia Repair in Australia: A Cost-Consequence and Budget Impact Analysis

    Dec 1, 2024, 00:00

  • EE321 Hospitalization Burden of Congenital Adrenal Hyperplasia in New England: A Six-Cohort Analysis of National In-Patient Data (2016-2020)

    Dec 1, 2024, 00:00

  • EPH175 Baseline Risk of Hospitalization and Death in a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE259 Pharmacists as Advocators for Influenza Vaccination in Elderly Patients: A Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • EPH148 Medical Costs of Adults With COVID-19 in Guatemala During the Endemic Phase: A Micro-Costing Study

    Dec 1, 2024, 00:00

  • EE648 Micro-Costing Study of Comprehensive Genomic Profiling for Implementation of Precision Cancer Medicine in Public Healthcare Systems: The Norwegian Infrastructure for Precision Diagnostics and Impress-Norway Trial

    Dec 1, 2024, 00:00

  • HTA210 Effectiveness of Generic Quality of Life (QoL) Questionnaires in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2024, 00:00

  • HTA22 Are NICE Methods Appropriate for Rare Diseases That Do Not Meet the HST Criteria?

    Dec 1, 2024, 00:00

  • HTA134 Implications of Indication Expansions on Pricing and Reimbursement and How This Differs Between EU4 and UK Markets

    Dec 1, 2024, 00:00

  • CO109 Evaluating the Psychometric Properties of the Brazilian Portuguese EQ Health and Well-Being Short Form (EQ-HWB-S)

    Dec 1, 2024, 00:00

  • HPR219 Studies on Health Economics and Outcomes From Türkiye Published in ISPOR by the Year 2024

    Dec 1, 2024, 00:00

  • HSD136 Assessing Gaps in the Timely Referral of Patients for a Rare Disease Diagnosis: A Cross-Sectional Survey of Physicians in Europe

    Dec 1, 2024, 00:00

  • EE253 Health Care Visits and Out-of-Pocket Costs in People With Chronic Hand Eczema

    Dec 1, 2024, 00:00

  • EE746 Budget and Organizational Impact Models (OBIM) for Health Products in Europe: An Overview from 2014 to 2024

    Dec 1, 2024, 00:00

  • EE256 Darolutamide As a Leading Option to Manage Prostate Cancer

    Dec 1, 2024, 00:00

  • HSD36 Medical Devices Index 2023: Access and Sourcing in Portuguese Hospitals, Challenges and Opportunities

    Dec 1, 2024, 00:00

  • HSD103 Scoping Review on Attitudes and Barriers Towards Therapeutic Drug Monitoring for Biological Treatments for Immune-Mediated Inflammatory Diseases Among Key Stakeholders

    Dec 1, 2024, 00:00

  • EPH134 Home Sweet Hospital: Evaluating Evidence Gaps and Future Research Priorities for Hospital at Home

    Dec 1, 2024, 00:00

  • HTA9 Cross Analysis of HAS Conclusions Amongst Products With an Economic Opinion Posted in 2023

    Dec 1, 2024, 00:00

  • EPH278 Trends in Epidemiology and Mortality of Patients With Lung Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE429 Insights From an Expert Advisory Board: The Trends Driving Changes in Managed Care

    Dec 1, 2024, 00:00

  • EPH154 Long-Term Incident Heart Failure After Acute Coronary Syndrome: A Population-Based Analysis

    Dec 1, 2024, 00:00

  • HPR70 Distribution of Prescriptions From Medical Institutions to Pharmacies in Japan: An Analysis of Health Insurance Claims Database

    Dec 1, 2024, 00:00

  • EE394 Optimized Patient Pathway for Aortic Stenosis Patients: The Economic and Clinical Implications

    Dec 1, 2024, 00:00

  • EPH70 Association Between Sleep Disorders and Subsequent Depression in Children and Adolescents: A Retrospective Cohort Study With 62,796 Patients in Germany

    Dec 1, 2024, 00:00

  • EE262 Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective

    Dec 1, 2024, 00:00

  • EPH138 Identifying and Profiling Patients With Heart Failure in a Population-Based Cohort Through Linkage of Primary and Secondary Care Data

    Dec 1, 2024, 00:00

  • EPH269 Changes in the Prevalence of Early Onset Dementia and Mild Cognitive Impairment in 2020-2023 Compared to 2010-2013 in German General Practices

    Dec 1, 2024, 00:00

  • HSD97 Clinicopathological Features Associated With the High Risk of Recurrence of Stage II Colorectal Cancer: Variability Among Guidelines and Studies, and Potential Implications for Market Access

    Dec 1, 2024, 00:00

  • Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists

    Dec 1, 2024, 00:00

  • HSD132 An Integral Approach to Assess the 3 Human Normal Immunoglobulin Formulations for Primary Immunodeficiency in Portugal: Combining Costs, Patient's Preferences, and HCP Choices

    Dec 1, 2024, 00:00

  • CO63 Clinical Meaningfulness of Improvements in Quality of Life Observed With Garadacimab Treatment in Patients Living With Hereditary Angioedema: Results From the Pivotal Phase 3 (VANGUARD) Study

    Dec 1, 2024, 00:00

  • EE280 Impact of COVID-19 on Healthcare Utilization and Costs: A Detailed Analysis From Inpatient and Outpatient Perspectives

    Dec 1, 2024, 00:00

  • HTA34 How Can the Marketing Authorization Holders Be Ready for the Implementation of the Joint Clinical Assessments in 2025?

    Dec 1, 2024, 00:00

  • HTA13 Is Carer Burden a Given When Modelling Spinal Muscular Atrophy? Examining NICE Submissions

    Dec 1, 2024, 00:00

  • HPR209 Pivotal Studies for Rare Diseases: Will They Better Support Market Access?

    Dec 1, 2024, 00:00

  • HPR29 Impact of Diagnosis-Related Groups (DRG) Payment on the Quality and Efficiency of Peripheral Arterial Disease (PAD) Care: A Mixed-Methods Study

    Dec 1, 2024, 00:00

  • HPR217 Analysis of Public Health Insurance Expenditures in Türkiye by Social Security Institution Between 2020 and 2023

    Dec 1, 2024, 00:00

  • EPH40 Challenges and Issues of Patients Living With HIV in Algeria: Current Epidemiological Situation

    Dec 1, 2024, 00:00

  • EPH209 Incidence of Pulmonary Nodules (PNs) in 2019 in the United States

    Dec 1, 2024, 00:00

  • EE632 Early Cost-Effectiveness of SPECTRISTM (Gamma Band Stimulation) in Mild-Moderate Alzheimer's Disease Patients

    Dec 1, 2024, 00:00

  • EE793 An Early Economic Evaluation to Identify the Necessary Test Characteristics of Novel Biomarker Tests for Giant Cell Arteritis

    Dec 1, 2024, 00:00

  • EPH23 The Use of Machine Learning Techniques for Healthcare Cost Prediction: A Preliminary Analysis of Administrative Databases From a Health Protection Agency in Northern Italy

    Dec 1, 2024, 00:00

  • EE384 The Economic Impact of Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Retinopathy (DR), and Diabetic Macular Edema (DME): A Systematic Literature Review of the Emerging Literature

    Dec 1, 2024, 00:00

  • EE819 How Can Discrete Choice Experiment Method Improve Patient Care and Engagement? An Example in the Field of Fertility

    Dec 1, 2024, 00:00

  • PT8 Access to Orphan Medicines in Ireland

    Dec 1, 2024, 00:00

  • EE275 Real-World Healthcare Resource Utilization and Costs in Patients With Locally Advanced or Metastatic Urothelial Carcinoma in China

    Dec 1, 2024, 00:00

  • CO29 An Ensemble Approach to Predicting Overall Survival (OS) Benefit Jointly From Multiple Surrogate Endpoints (SE) in Oncology: A Case Study in Previously Untreated Metastatic Melanoma

    Dec 1, 2024, 00:00

  • EPH139 Prevalence and Disease Burden of Disease-Related Malnutrition in Hospitalized Patients in Spain

    Dec 1, 2024, 00:00

  • HPR222 European Reimbursement Process Overview of Digital Medical Device

    Dec 1, 2024, 00:00

  • Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in Germany

    Dec 1, 2024, 00:00

  • EE468 A Systematic Review of Health Economic Evaluation on Therapies for the Treatment of Inherited Retinal Diseases: A Quality Evaluation

    Dec 1, 2024, 00:00

  • HPR21 The Impact of the Health Act (Pricing and Supply of Medical Goods) (2013) on the Pricing of Medicines in Ireland

    Dec 1, 2024, 00:00

  • EE692 Uncovering the Blind Spot: A Targeted Search of Placebo Effect Adjustments in Submissions to the National Institute for Health and Care Excellence

    Dec 1, 2024, 00:00

  • EE303 Adult Immunization With Tetanus, Diphtheria, and Pertussis Vaccine for at-Risk Populations (Asthma, COPD, HIV) for the Prevention of Pertussis in Colombia

    Dec 1, 2024, 00:00

  • EE649 Prerequisites for Cost-Effective Home Blood Pressure Telemonitoring: Insights From an Early Health Economic Analysis

    Dec 1, 2024, 00:00

  • HPR25 Assessing Sustainable Biosimilar Competition: Current Trends and Impacts of Anti-TNF Biosimilar Competition in Europe

    Dec 1, 2024, 00:00

  • HTA177 Reasons for Drug Market Access Failure in Portugal: A Retrospective Analysis of Public Reimbursement Reports

    Dec 1, 2024, 00:00

  • EE495 Cost-Effectiveness of a Comprehensive HBV Screening and Management Program in China: A Real-World Data Analysis From Huazhou City

    Dec 1, 2024, 00:00

  • HSD137 The Value Proposition of Remote Monitoring in Heart Failure: Pains and Gains Towards Patients’ Adoption

    Dec 1, 2024, 00:00

  • EPH110 Trends in Epidemiology and Mortality of Patients With Colorectal Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EPH57 Real-World Data of Severe Viral Lower Respiratory Tract Disease; Current Landscape, Challenges, and Future Recommendations

    Dec 1, 2024, 00:00

  • EPH207 Incidence and Prevalence of Idiopathic Pulmonary Fibrosis (IPF): A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • EPH239 Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations

    Dec 1, 2024, 00:00

  • HTA158 A Comprehensive Review of NICE Highly Specialized Technology Appraisals

    Dec 1, 2024, 00:00

  • EPH63 Prevalence and Risks of Mental Health Issues During the Postnatal Period

    Dec 1, 2024, 00:00

  • HTA142 Use of External Control Arms in Reimbursement Submissions: A Review of CAR-T Appraisals by NICE and CDA

    Dec 1, 2024, 00:00

  • CO82 Long-Acting Somatostatin Analogues Treatment Patterns and Outcomes in Neuroendocrine Tumor Patients: An Italian Propensity Score Matched Cohort Study

    Dec 1, 2024, 00:00

  • EE474 Valuation and Exploitation of Sick Leaves Identified in the French SNDS Database

    Dec 1, 2024, 00:00

  • HTA170 Use of Off-Label Comparators in Health Technonology Assessment in Portugal: A Review of Reimbursement Appraisal Reports

    Dec 1, 2024, 00:00

  • EE557 A Systematic Review of Productivity Gain/Loss in Health Economic Evaluations: An Element for Value Assessment of Innovative Treatments

    Dec 1, 2024, 00:00

  • HTA227 Evaluating the Importance of Patient Input in NICE Highly Specialized Technology (HST) Assessments: Insights From Review Reports

    Dec 1, 2024, 00:00

  • HPR238 FDA vs EMA a Comparison of New Chemical Entity Approvals: The Role of Start-Ups

    Dec 1, 2024, 00:00

  • EPH285 The Influence of Health Literacy on the Selection of Healthcare Facilities: An Association Between Health Literacy Level and Number of Healthcare Facilities Visited per Patient per Year Using Real World Data in Japan

    Dec 1, 2024, 00:00

  • EPH246 Comparison of Approval Dates of New Medications Between Europe (European Medicines Agency, EMA), Japan (Pharmaceutical and Medical Devices Agency, PMDA), and the United States (US) of America (Food and Drug Administration, FDA)

    Dec 1, 2024, 00:00

  • HTA185 From Plan to Action: Assessing the Impact of the NICE Real-World Evidence Framework Following Its Introduction in June 2022

    Dec 1, 2024, 00:00

  • EPH257 Impact of Fragility Fractures in the Bolívar Department, Colombia

    Dec 1, 2024, 00:00

  • CO15 Real-World Treatment Usage of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Belgium: Results of the AREVEDECY Study

    Dec 1, 2024, 00:00

  • HTA112 Can Excess Hazard Models Enhance Survival Analysis in Health Technology Assessments?

    Dec 1, 2024, 00:00

  • HPR149 An Update on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reimbursed Under a Managed Access Protocol in Ireland

    Dec 1, 2024, 00:00

  • CO120 Assessment of Metformin Failure Among Patients With Type 2 Diabetes Mellitus at a Tertiary Care Center in Central India

    Dec 1, 2024, 00:00

  • EPH125 How Do We Refer to Individuals in the Scientific Literature? Use of 'Person-First' Language vs 'Condition-First' Language in Oncology Medical Journals

    Dec 1, 2024, 00:00

  • HSD38 Continuity of Medication Care for Cancer Patients Through Outpatient Service Provision in Specialist Practices in Germany

    Dec 1, 2024, 00:00

  • HTA119 Assessing a Potential Framework to Prioritise Generalised Cost-Effectiveness Analysis (GCEA) Value Elements in Future Decision Making by Evidence and Relevan Case Study Across Oncology and Infectious Diseases

    Dec 1, 2024, 00:00

  • HTA65 Exploring PICO Variations in Relapsed or Refractory DLBCL in the Context of the European Joint Clinical Assessment

    Dec 1, 2024, 00:00

  • EPH8 Risk of Acute Pancreatitis Associated With ARBs and ACE Inhibitors: A Meta-Analysis of Observational Studies

    Dec 1, 2024, 00:00

  • EPH127 Drivers and Consequences of Plasma-Derived Medicinal Product Shortages

    Dec 1, 2024, 00:00

  • HPR186 Developing a Value Framework to Determine New Drugs Price Premium Using Multi-Criteria Decision Analysis Approach: SFDA Experience

    Dec 1, 2024, 00:00

  • HTA74 Incorporating Environmental Sustainability Into Health Technology Assessments: Two Adapted Cost-Utility Analyses (CUA) of Insulin Icodec Versus Degludec for Type 2 Diabetes (T2D) Management in England

    Dec 1, 2024, 00:00

  • HPR14 The Landscape of Approved Drugs With Pediatric Orphan Indications in Saudi Arabia

    Dec 1, 2024, 00:00

  • HPR236 Assessing the Reimbursement Landscape of Oncology Products in the Turkish Pharmaceutical Market

    Dec 1, 2024, 00:00

  • EE652 Budget Impact of Lecanemab for Alzheimer's Disease Patients Among Medicare Beneficiaries in the United States: A Subgroup Analysis

    Dec 1, 2024, 00:00

  • HTA96 The Increasing Use of Real-World Data in Health Technology Appraisals of Oncology Therapies: A Systematic Review

    Dec 1, 2024, 00:00

  • EE707 In-Office Versus Operating Room Hysteroscopic Resection of Endometrial Polyps: A Cost Analysis From a Spanish Hospital Perspective

    Dec 1, 2024, 00:00

  • HSD91 Integrated Care Process and Pharmacological Prescription for Patients With Hypercholesterolemia or Mixed Dyslipidemia at High or Very High Cardiovascular Risk in Catalonia

    Dec 1, 2024, 00:00

  • EE477 A Budget Impact Analysis of Introducing Filgotinib for the Treatment of Rheumatoid Arthritis in Greece

    Dec 1, 2024, 00:00

  • EPH113 Impact of Indoor Air Pollution on Health in Low-to-Middle Income Countries

    Dec 1, 2024, 00:00

  • EE695 Applying NICE's Disease Severity Modifier to the Context of Cancer Screening

    Dec 1, 2024, 00:00

  • CO52 Relationship Between Hemoglobin Levels and EQ-5D-5L Utility Index in Patients With Cold Agglutinin Disease

    Dec 1, 2024, 00:00

  • HSD58 Care Pathway of Patients With Neovascular Age-Related Macular Degeneration Treated by Anti-VEGF in France, Using Clustering Analysis Combined With Optimal Matching

    Dec 1, 2024, 00:00

  • EE669 Analysis of the Costs and Carbon Footprint Associated With Reusable Flexible Cystoscopes: Implications for the Utilization of Single-Use Digital Flexible Cystoscopes

    Dec 1, 2024, 00:00

  • EPH135 Real-World Prescribing Patterns of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Germany

    Dec 1, 2024, 00:00

  • PT7 Reassessment Dynamics of Orphan Drugs in Germany’s Benefit Assessment Process

    Dec 1, 2024, 00:00

  • EE653 Cost-Effectiveness of Adjuvant Olaparib for Patients With Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Breast Cancer in Portugal

    Dec 1, 2024, 00:00

  • EPH14 Gastrointestinal Endoscopy Volume, Efficiency, and Safety Issues: A Case Report

    Dec 1, 2024, 00:00

  • CO27 Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Canadians: A Systematic Literature Review and Meta-Analysis Using the Grade Framework

    Dec 1, 2024, 00:00

  • EE426 Cost-Effectiveness of Switching From PCV13 to PCV20 in the Portuguese Childhood National Immunization Program

    Dec 1, 2024, 00:00

  • HSD6 Feasibility of Healthcare Quality Indicators for Breast Cancer in China: A Real-Word Study

    Dec 1, 2024, 00:00

  • EPH66 How Real Is Your Real-World Evidence (RWE)? Demonstration of the Need for Comprehensive Real-World Data (RWD) to Examine Patient Burden and Disease Journey in Patients With Sickle Cell Disease (SCD) in the United States (US)

    Dec 1, 2024, 00:00

  • EE837 Cost Effectiveness of Nirsevimab and Maternal RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus Disease Among Infants in the United States

    Dec 1, 2024, 00:00

  • HTA189 Alignment of EU HTA and Member State Clinical Assessments and the Potential Impact on Value Perception

    Dec 1, 2024, 00:00

  • HPR17 National Reimbursement Drug List in China: Changing Dynamics and Trend and Price Determination of Formulation Innovation Drugs

    Dec 1, 2024, 00:00

  • EPH51 Evaluation of US/European Deprivation Indices Applications in Oncological, Health Economics, and Outcomes Research (HEOR) Studies

    Dec 1, 2024, 00:00

  • EE568 Economic Evaluation of the Co-Formulated Antiretroviral Efavirenz 400mg/Lamivudine/Tenofovir Disoproxil Fumarate for the Treatment of HIV-1 Infection in Adult Patients From the Perspective of the Mexican Public Health System

    Dec 1, 2024, 00:00

  • P4 Bias Reduction in Indirect Treatment Comparison of Time-to-Event Outcomes: A Case Study on Application of ML-NMR Versus MAIC Using Simulated Dataset

    Dec 1, 2024, 00:00

  • HTA232 Review of Real-World Evidence (RWE) in Marketing Authorization Applications (MAAs) Highlight Differences in Evidentiary Standards Among Regulatory and Health Technology Assessment (HTA) Bodies

    Dec 1, 2024, 00:00

  • HTA48 Evaluating the Relevance of Conditional Marketing Authorization for Successful HTA Outcomes in France

    Dec 1, 2024, 00:00

  • EE244 Economic Burden of Grade 3+ Adverse Event Management Associated With Dato-DXd and Docetaxel-Containing Regimens in Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: A European and USA Analysis

    Dec 1, 2024, 00:00

  • EE778 Early Cost-Consequence Analysis of Comprehensive Genomic Profiling in a Metastasized Tumor-Agnostic Population

    Dec 1, 2024, 00:00

  • HSD21 The Impact on Health Service Delivery of Providing an Alternative Telephone Pathway for Acute But Non-Urgent Healthcare Needs: A Scoping Review of International Practice

    Dec 1, 2024, 00:00

  • CO38 Burden and Trends of COPD Exacerbations in France Before and During the Pandemic

    Dec 1, 2024, 00:00

  • EPH158 Assessing the Public Health Benefit of a mRNA-Based Respiratory Syncytial Virus Vaccine (mRNA-1345) Among Adults ≥65 Years in France

    Dec 1, 2024, 00:00

  • Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom

    Dec 1, 2024, 00:00

  • EPH213 A Real-World Evidence Study Describing Characteristics of Patients Receiving a CVD Risk Assessment in Primary Care in England Between 2013 and 2023

    Dec 1, 2024, 00:00

  • EE759 Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma

    Dec 1, 2024, 00:00

  • HTA106 How Has Treatment Switching Been Accounted for? Insights From NICE Appraisals

    Dec 1, 2024, 00:00

  • HPR177 Modeled Impact of Risk-Sharing Agreements on Costs for Hemophilia B Gene Therapy in Germany

    Dec 1, 2024, 00:00

  • EE282 Budget Impact Analysis of Ivosidenib in Combination With Azacitidine for the Treatment of Previously Untreated mIDH1 Positive Acute Myeloid Leukaemia (AML) Patients, Ineligible for Intensive Induction Chemotherapy in Greece

    Dec 1, 2024, 00:00

  • HPR153 Analysis of Annual-Cost Threshold for Drugs Reimbursement Decisions in China

    Dec 1, 2024, 00:00

  • EE301 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Lenvatinib for the Treatment of Advanced Second-Line Endometrial Cancer

    Dec 1, 2024, 00:00

  • EPH37 Adult Vaccinations in Europe: Unfulfilled Potential

    Dec 1, 2024, 00:00

  • PT13 Cost-Effectiveness Analysis of Stool-Based Colorectal Cancer Screening Tests for Individuals Aged 45 Years

    Dec 1, 2024, 00:00

  • EE636 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Spain

    Dec 1, 2024, 00:00

  • HTA184 Uncertainty Appraisal in Economic Opinions of the French National Authority for Health

    Dec 1, 2024, 00:00

  • EE722 Assessing Healthcare Resource Use and Burden Among an Older Population of Patients With Respiratory Syncytial Virus in Five European Countries Using Real-World Data

    Dec 1, 2024, 00:00

  • EE378 Health Economic Impact of Maternal Bivalent Stabilized Prefusion F Subunit Vaccine for Prevention of Respiratory Syncytial Virus Infections Among Infants in Germany

    Dec 1, 2024, 00:00

  • HSD76 Treatment Utilization and Treatment Duration of Patients With Psoriasis Diagnosed With Psoriatic Arthritis in a US Commercial Administrative Claims Database

    Dec 1, 2024, 00:00

  • EE755 Substantial Healthcare Resource Utilization in Patients Diagnosed With Viral Lower Respiratory Tract Disease in Spain

    Dec 1, 2024, 00:00

  • EPH130 The Humanistic Burden and Productivity Lost From Atopic Dermatitis in Central and Eastern European Countries

    Dec 1, 2024, 00:00

  • HTA12 The Cost-Effectiveness of Immunotherapies for Advanced or Recurrent Endometrial Cancer: A Systematic Review

    Dec 1, 2024, 00:00

  • HTA203 Dynamic Vaccine Valuation: A Method Framework for Early Health Technology Assessment, Driving Innovation, and Implementation Strategies

    Dec 1, 2024, 00:00

  • EPH61 Sex-Related Disparities in Chronic Cough Reported by Adults in the United States

    Dec 1, 2024, 00:00

  • EPH71 A Systematic Review and Meta-Analysis of Interval Cancer of Stool Testing for Colorectal Cancer Screening

    Dec 1, 2024, 00:00

  • HTA207 Robotic Surgery in Oncology: Results From a Multidimensional Assessment in Italy

    Dec 1, 2024, 00:00

  • HTA54 Review of Cell and Gene Therapies by NICE, HAS, and G-BA: How Did They Fare?

    Dec 1, 2024, 00:00

  • HPR127 The Cost Effectiveness of Collaborative Dementia Care for Alzheimer's Disease Relative to Disease Modifying Therapies

    Dec 1, 2024, 00:00

  • EE757 Cost-Effectiveness of DNA Methylation as Triage for Cervical Cancer Screening in Hong Kong: A Modelling Study

    Dec 1, 2024, 00:00

  • P13 Development of a Goal Attainment Scale (GAS) and Global Impression (GI) Items for Use As Outcome Measures in Intervention Studies in Pediatric Autism

    Dec 1, 2024, 00:00

  • PT25 Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer

    Dec 1, 2024, 00:00

  • HSD44 Physical Therapy in Patients With Pulmonary Arterial Hypertension (PAH): Results From a German Claims Data Analysis

    Dec 1, 2024, 00:00

  • EE763 Indirect Costs in 5 Types of Cancer in Adults in Mexico From 2024 to 2030

    Dec 1, 2024, 00:00

  • EE337 Cost-Effectiveness of [177Lu]Lu-PSMA-617 in Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2024, 00:00

  • EE527 Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar

    Dec 1, 2024, 00:00

  • EE308 The Economic Burden of Alcohol in Belgium: Incremental Healthcare and Indirect Costs

    Dec 1, 2024, 00:00

  • HTA75 Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey

    Dec 1, 2024, 00:00

  • EE240 Evaluating the Impact of Matched-Adjusted Indirect Comparisons on Propagated Uncertainty in Economic Outcomes

    Dec 1, 2024, 00:00

  • EPH31 Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)

    Dec 1, 2024, 00:00

  • P50 Technical Validation of an Environmental Model of Aurora EV-ICD: Recommendations to Guide Environmental Criteria in Health Technology Assessment

    Dec 1, 2024, 00:00

  • HSD4 Management of Guillain-Barré Syndrome: A Systematic Review of Clinical Practice Guidelines

    Dec 1, 2024, 00:00

  • HTA165 A Comparative Analysis of Reimbursement Outcomes for Orphan Drugs Between EU and Non-EU Countries

    Dec 1, 2024, 00:00

  • HPR207 How Long Is Long Enough? Data Collection Duration for Medicines in Managed Access in England

    Dec 1, 2024, 00:00

  • HPR117 The Economic Burden of Lung Cancer in Gree A Systematic Review of the Literature

    Dec 1, 2024, 00:00

  • EPH121 Minimum Legal Age of Tobacco Sales Law as a Commitment Mechanism: A Regression Discontinuity Design

    Dec 1, 2024, 00:00

  • Disclaimer

    Dec 1, 2024, 00:00

  • EPH183 Utilization and Expenditure on Medicines for the Prevention and Treatment of Osteoporosis: A Changing Landscape

    Dec 1, 2024, 00:00

  • HPR160 Integrating Healthcare System Value Into New Medicine Evaluations for Timely and Full Patient Access

    Dec 1, 2024, 00:00

  • EE622 Direct Healthcare Costs of Incident Heart Failure After Acute Coronary Syndrome

    Dec 1, 2024, 00:00

  • EE597 Budget Impact Analysis of Introducing Benralizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: A European Perspective

    Dec 1, 2024, 00:00

  • Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data

    Dec 1, 2024, 00:00

  • HPR52 Macroeconomic Regulation of Drug Expenditures in Europe: Lessons for the French Safeguard Clause From a Scoping Review

    Dec 1, 2024, 00:00

  • HTA39 Using Environmental Impact Data to Support Health Technology Assessment at NICE: An Options Appraisal

    Dec 1, 2024, 00:00

  • EE518 Economic Evaluations of Anifrolumab for the Management of Patients Affected by Systemic Lupus Erythematosus (SLE) in Italy

    Dec 1, 2024, 00:00

  • HSD95 Economic Results of a Model for the Detection of Pharmacological Inefficiencies in Patients With Chronic Diseases

    Dec 1, 2024, 00:00

  • HTA226 Lack of Face Validity in Health Technology Assessments: Systematic Review of NICE Assessments and Lessons Learned

    Dec 1, 2024, 00:00

  • EE398 Direct and Indirect Benefits of Clinical Trials for the Public Health Care: Finnish Society Gains 10 Million Euros of Value Per Trial

    Dec 1, 2024, 00:00

  • P42 EQ-5D-5L Mapping Function Recently Recommended by NICE Is Likely to Generate Higher Utility Values

    Dec 1, 2024, 00:00

  • EE824 Are Standard Economic Evaluations Suitable for Evaluating Life-Extending Innovations in Kidney Care?

    Dec 1, 2024, 00:00

  • EPH97 Characteristics of Cannabis-Based Consumer Health Products Users in Community Pharmacies in Portugal

    Dec 1, 2024, 00:00

  • EE629 Estimating the Carbon Intensity Profile of a Biologic for the Treatment of Chronic Obstructive Pulmonary Disease in the United Kingdom

    Dec 1, 2024, 00:00

  • EE840 Assessing Direct Medical Costs of Stage IV NSCLC in Iraq From Public Payer Perspective

    Dec 1, 2024, 00:00

  • EPH251 Estimate of Brazilian Population in Secondary Prevention of Cardiovascular Disease in Public Healthcare System: Evaluating Potential Need for Lipid-Lowering Treatment Beyond Statin and Ezetimibe

    Dec 1, 2024, 00:00

  • HSD119 How a Government Policy Can Have a Positive Impact on Women's Choice of Contraception: A Study of Irish Pharmacy Sales Data Between the Years 2021-2024

    Dec 1, 2024, 00:00

  • EPH119 RSV-Passive Immunization Reduces Antimicrobial Consumption During RSV Infection in Infants and Young Children 5 Years in Japan

    Dec 1, 2024, 00:00

  • EE506 Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica

    Dec 1, 2024, 00:00

  • HTA59 Assessing Efficiencies of AI-Powered Tools in Reporting Healthcare Economics and Outcomes Research (HEOR) Data for Health Technology Assessment (HTA) Submissions

    Dec 1, 2024, 00:00

  • EE560 Potential Budget Impact of Using a Cyanoacrylate Polymer Barrier Film Versus Traditional Method for the Prevention of Incontinence-Associated Dermatitis in a Hospital Setting in New Zealand

    Dec 1, 2024, 00:00

  • EE528 Cost-Effectiveness Analysis of the TAK-003 Dengue Vaccine Introduction in Argentina

    Dec 1, 2024, 00:00

  • EPH159 Estimating the Remaining Chronic HCV Prevalence in Ireland: A Risk Population Modelled Approach Applied in Practice

    Dec 1, 2024, 00:00

  • HTA230 Indirect Treatment Comparisons in NICE Highly Specialized Technology Assessments

    Dec 1, 2024, 00:00

  • EE491 A Budget Impact Analysis of a New Treatment for Adults With Homozygous Familial Hypercholesterolaemia

    Dec 1, 2024, 00:00

  • CO91 Validation of Clinical Response Rates Extrapolated With Dose-Response Estimation Methods in Chronic Hepatitis Delta

    Dec 1, 2024, 00:00

  • HTA64 Leveraging Machine Learning for Predicting Health Technology Assessment Outcomes

    Dec 1, 2024, 00:00

  • HSD84 Towards a Frictionless CAR-T Therapy Process: Identifying and Prioritizing Procedural Preconditions for Oncologic Institutions Using Group Concept Mapping

    Dec 1, 2024, 00:00

  • EE782 The Landscape of Pre-Exposure Prophylaxis (PrEP) in Brazil: Challenges, Advances, and Opportunities As a Public Health Strategy in the Battle Against HIV/AIDS

    Dec 1, 2024, 00:00

  • HTA69 Vaccines and EU HTA: Exploring Misalignments Between Joint Clinical Assessment Requirements and a Hypothetical Vaccine Evidence Package

    Dec 1, 2024, 00:00

  • HPR140 Using Safety Engineered Intravenous Access Devices in Malaysia to Reduce Needle Stick Injuries: A Meta-Analytic Synthesis of Literature Health System Projection

    Dec 1, 2024, 00:00

  • EPH161 Psychiatric Multimorbidity and Risk of Dementia: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Healthcare Data

    Dec 1, 2024, 00:00

  • EPH230 Geographic Variation in Routine Childhood Vaccination Using Real-World Eviden Pre- and Post- COVID-19 Pandemic

    Dec 1, 2024, 00:00

  • EE836 Cost-Effectiveness of Zolbetuximab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Adenocarcinoma in Taiwan

    Dec 1, 2024, 00:00

  • HTA42 Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines (2021-2022)

    Dec 1, 2024, 00:00

  • EE783 Cost-Effectiveness Analysis of an Advanced Hybrid Closed Loop System Versus Standard of Care in the Management of Type 1 Diabetes in the Netherlands

    Dec 1, 2024, 00:00

  • HTA225 Optimizing HTA Outcomes in Cost-Effectiveness Markets: A Case Study of Axicabtagene Ciloleucel

    Dec 1, 2024, 00:00

  • CO133 Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients With Obesity: A Bayesian Network Meta-Analysis of GLP-1 RCTs

    Dec 1, 2024, 00:00

  • HSD11 Patient Journey Mapping of the Gene Therapy in Hemophilia B in Spain: The Bhemogen Project

    Dec 1, 2024, 00:00

  • HTA183 A General Framework for Early Health Technology Assessment (eHTA) to Support the Development of New Radiology Artificial Intelligence (AI) Tools

    Dec 1, 2024, 00:00

  • EE409 The Economic Impact of Early Comprehensive Genomic Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer Patients: Real World Evidence From a Brazilian Private Healthcare Provider Database

    Dec 1, 2024, 00:00

  • EE507 Deriving Decision Uncertainty Associated With Calibration Target Data: A Value of Information Approach

    Dec 1, 2024, 00:00

  • EE522 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab in Adolescents With Severe Atopic Dermatitis in Spain

    Dec 1, 2024, 00:00

  • HSD100 Economics of a Virtual Care Model for Diagnosis and Treatment of Sleep Apnea in Germany: Results From a Cost-Consequence Analysis

    Dec 1, 2024, 00:00

  • EE237 Cost-Minimization Analysis for Soliqua in the Treatment of T2DM in Turkiye

    Dec 1, 2024, 00:00

  • EE421 A Budget Impact Analysis of Azelastine Hydrochloride/Fluticasone Propionate (AzeFlu) Nasal Spray Suspension for Patients With Allergic Rhinitis (AR) in the Kingdom of Saudi Arabia

    Dec 1, 2024, 00:00

  • EE691 Cost Estimation of Managing Retinitis Pigmentosa in France in a Multi-Payer Environment From a Societal Perspective

    Dec 1, 2024, 00:00

  • EE325 Hospitalizations From Veno-Occlusive Disease in the US Pacific Region: A Six-Cohort Analysis of National In-Patient Data (2016-2020)

    Dec 1, 2024, 00:00

  • HPR4 Analyzing the Impact of EU5 and UK Pricing Reforms: A Pathway to Adaptation in an Evolving Policy Landscape

    Dec 1, 2024, 00:00

  • EE585 Increasing Conscious Sedation Use for Dental Treatments: A Cost and Consequences Analysis

    Dec 1, 2024, 00:00

  • HSD134 Prescribers' Opinions, Preferences and Attitudes on Deprescribing for Patients With Diabetes in China: A Nationwide Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • EPH10 Dynamics of Self-Medication Among Expectant Mothers in a City in Southeast Nigeria

    Dec 1, 2024, 00:00

  • HSD33 Over a Decade of Trends in Gabapentinoid Prescribing and Daily Doses Among Patients Taking Opioids for Pain Management in Malaysia (2010-2020)

    Dec 1, 2024, 00:00

  • HPR208 Does the Improvement of Medical Insurance Equity Enhance the Mental Health of Elderly Residents in Rural Areas? Evidence From the Adjustment of Medical Insurance Policy in China

    Dec 1, 2024, 00:00

  • HTA137 The Changing Landscape of Health Technology Assessment (HTA) in the Asia-Pacific (APAC) Region: Advances, Challenges, and Future Goals

    Dec 1, 2024, 00:00

  • EE355 The Impact of Dynamic Mortality on the Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in France

    Dec 1, 2024, 00:00

  • EE732 From Pipeline to Pricing Reimbursement: Economic Impact and Access Challenges of Upcoming Gene Therapies

    Dec 1, 2024, 00:00

  • HSD30 Hospital Methodology for Steering on Patient Value: Healthcare Outcomes in Relation to Costs

    Dec 1, 2024, 00:00

  • EE442 Cost-Utility Analysis and Efficiency Frontier Approach of Tafasitamab in Brazilian Private Healthcare System Perspective

    Dec 1, 2024, 00:00

  • PT16 Economic Influences on Medical Decision-Making in Cancer Medicine: An Analysis of Qualitative and Quantitative Data

    Dec 1, 2024, 00:00

  • EPH1 Universal Health Coverage and Education Are the Decisive Socio-Economic Disparities in Cervical Cancer Mortality in the Dominican Republic: A Multi-Dimensional Ecological Approach in a Middle-Income Caribbean Country

    Dec 1, 2024, 00:00

  • The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study

    Dec 1, 2024, 00:00

  • HTA153 Health Equity Priorities for Pharmaceutical Manufacturers: Payer Perceptions From a Global Survey

    Dec 1, 2024, 00:00

  • EE439 A Multiple Myeloma Case Study for Incorporating Carbon Footprint in Health Technology Assessment

    Dec 1, 2024, 00:00

  • HPR86 Frequency and Variation of Clock-Stop During EMA Assessment for Oncology Products: Implication on JCA Timelines

    Dec 1, 2024, 00:00

  • EE592 Performance Evaluation of Explainable Artificial Intelligence to Replicate a Systematic Review and Meta-Analysis of Cost-Effectiveness Analysis Findings

    Dec 1, 2024, 00:00

  • CO79 Effectiveness of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa: Results From a Meta-Analysis

    Dec 1, 2024, 00:00

  • EE637 Assessment of Clinically Meaningful Benefits and Incremental Costs of Adding Bevacizumab to Trifluridine/Tipiracil for Metastatic Colorectal Cancer: A Comparison With Other Combination Regimens

    Dec 1, 2024, 00:00

  • EE386 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland

    Dec 1, 2024, 00:00

  • HTA166 Beyond RCTs: The Role of Real-World Evidence in NICE Submissions for Rare Diseases

    Dec 1, 2024, 00:00

  • EE363 Use of Artificial Intelligence in Stress Echocardiography in NHS Coronary Artery Disease Risk Prediction: A Cost Effectiveness Analysis Study

    Dec 1, 2024, 00:00

  • EE790 Cost-Effectiveness and Cost Utility Analysis of an eHealth Peer-Led Wheelchair Training Program Compared to the Existing Wheelchair Training Practice in Canadian Rehabilitation Centers: Economic Evaluation of a RCT

    Dec 1, 2024, 00:00

  • EPH284 Exploring the Association Between Health Literacy and Depression Prevalence Through Personal Health Record Associated With Health Insurance Claims Data

    Dec 1, 2024, 00:00

  • EPH39 Economic Implications of Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patient Characteristics, Unmet Needs, and Cost-Effectiveness

    Dec 1, 2024, 00:00

  • HPR111 Comparing Factors Influencing Price Elasticity of Pharmaceuticals and Value-Based Pricing Across Europe and the USA

    Dec 1, 2024, 00:00

  • CO56 Retrospective Non-Interventional Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients With Non-Muscle-Invasive Bladder: Real-World Experience From Six Hospital Centers in Greece

    Dec 1, 2024, 00:00

  • HSD121 Change in Metabolic Syndrome of the Primary Care-Based National Lifestyle Intervention Program: An Observation Cohort Study

    Dec 1, 2024, 00:00

  • EE551 Cost-Minimization of Faricimab Vs Aflibercept 8 Mg in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Evaluating the Impact of Retreatment Criteria

    Dec 1, 2024, 00:00

  • HSD57 Safety and Contagion in Inpatient Mental-Health Wards: An Estimate of the Contagion Effect From the Wardsonar Study in the UK

    Dec 1, 2024, 00:00

  • EE588 Direct Costs of RSV Cases in Hospitalized Patients (Aged ≥60 Years) Identified From 2010-2020 in a Retrospective Study in Valladolid, Spain

    Dec 1, 2024, 00:00

  • P60 Socioeconomic Burden of Major Diseases in Eight Latin American Countries

    Dec 1, 2024, 00:00

  • Exploring the Association Between Surgical Out-of-Pocket Costs and Healthcare Quality Outcomes: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE242 Cost of Managing Brain Metastases in Patients With ALK-Positive Advanced NSCLC With First-Line ALK Tyrosine Kinase Inhibitors (TKIs) in China

    Dec 1, 2024, 00:00

  • HSD90 Towards Tomorrow: Transforming Sarcoma Care in Bulgaria

    Dec 1, 2024, 00:00

  • EE247 Fully Replicating Published Markov Health Economic Models Using Generative AI

    Dec 1, 2024, 00:00

  • EPH214 Epidemiological Disparities and Risk Factors of Esophageal Cancer in Türkiye: A Systematic Review

    Dec 1, 2024, 00:00

  • EE662 Estimated Clinical and Economic Burden of Obesity in Japan Over the Next 5 Years

    Dec 1, 2024, 00:00

  • HTA102 Are EU JCA Evidence Requirements Achievable? Insights From a Retrospective Evidence Analysis Study for Rare and Non-Rare EU Treatment Landscapes

    Dec 1, 2024, 00:00

  • HSD40 Therapeutic Decision-Making for Patients With Sickle Cell Disease (SCD) and How Research Findings Influence the Potential Use of Mitapivat

    Dec 1, 2024, 00:00

  • HPR214 Use of Multicriteria Decision Analysis (MCDA) for Includes Innovation in Public Health Policy Formulation: A Scoping Review

    Dec 1, 2024, 00:00

  • HTA95 Predicting Evidence Requirement Implications of the EU Joint Clinical Assessment (JCA) Through a Population, Comparator, Intervention, Outcome (PICO) Simulation for Two Anticancer Investigational Medicinal Products (IMPs)

    Dec 1, 2024, 00:00

  • HPR145 The Evolving Influence of the Inflation Reduction Act and Value Assessment in US Payer Decision-Making

    Dec 1, 2024, 00:00

  • EE789 Cost-Effectiveness of Tirzepatide Versus Liraglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective

    Dec 1, 2024, 00:00

  • EE500 Global Economic Burden of Retinitis Pigmentosa (RP): A Systematic Literature Review

    Dec 1, 2024, 00:00

  • HTA125 Comparison of the Joint Clinical Assessment (JCA) Dossier With the German Medicines Market Reorganization Act (AMNOG) Dossier: What Content Remains to Be Presented AMNOG Dossier After the Implementation of JCA?

    Dec 1, 2024, 00:00

  • P45 Optimizing Electronic Medical Records Data Completeness With On-Premise Artificial Intelligen A Study on Large Language Models Enhancing Medication Documentation

    Dec 1, 2024, 00:00

  • HSD24 Estimating the Global and EU27+UK Prevalence of Patients With Cancer in Palliative Care and Patients in Two Neurodegenerative Disorders Potentially Benefiting From Cannabinoid-Based Medicines

    Dec 1, 2024, 00:00

  • HTA82 A Blueprint for Success: The Importance of Multi-Stakeholder Alignment for EU Health Technology Assessment (HTA)

    Dec 1, 2024, 00:00

  • PT15 Utilization Trends and Access Disparities in CAR T-Cell Therapy: Real-World Insights From an All-Payer US Healthcare Database (2017-2024)

    Dec 1, 2024, 00:00

  • PT19 Emerging Trends in the Adoption of Alternative Financing Models for Advanced Therapy Medicinal Products: A Scoping Review

    Dec 1, 2024, 00:00

  • EE403 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in Germany

    Dec 1, 2024, 00:00

  • EE724 Healthcare Resources Utilization and Costs of Treatment Associated With Anogenital Warts in South Africa: Public and Private Perspective

    Dec 1, 2024, 00:00

  • CO122 Pharmacist-Driven Management of Type 2 Diabetes Improves HbA1c, Mortality, and Medical Costs in an Integrated Health System

    Dec 1, 2024, 00:00

  • EE489 Cost-Effectiveness of Zanubrutinib + Obinutuzumab for Treatment of Relapsed or Refractory Follicular Lymphoma in the United States

    Dec 1, 2024, 00:00

  • CO78 High-Efficacy Therapies (HETs) First Versus an Escalation Approach in Multiple Sclerosis: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EPH89 Medical Costs of Adults With COVID-19 in Costa Rica During the Endemic Phase: A Micro-Costing Study

    Dec 1, 2024, 00:00

  • HPR250 Reimbursement Decisions for Innovative Drug Technologies in Poland: Duration of Reimbursement Processes and Impact of HTA Recommendation

    Dec 1, 2024, 00:00

  • HTA130 Key Drivers Underlying Positive and Negative Decisions for National Institute for Health and Care Excellence (NICE) Technology Appraisals (TAS) and Highly Specialised Technology (HST) Appraisals in 2023

    Dec 1, 2024, 00:00

  • EE390 Potential Budget Impact of Using a Cyanoacrylate Polymer Barrier Film Compared to Traditional Methods for the Management of Incontinence-Associated Dermatitis for Residents of a Skilled Nursing Facility

    Dec 1, 2024, 00:00

  • EE838 Cost-Effectiveness of Momelotinib for Treatment of Myelofibrosis in Taiwan

    Dec 1, 2024, 00:00

  • EPH249 Epidemiology of Patients With Thymic Carcinoma in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE354 An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination With Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US

    Dec 1, 2024, 00:00

  • EPH167 Trends in Epidemiology and Mortality of Patients With Hypertension in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE713 Cost-Effectiveness of Adjuvant Nivolumab for Patients With Stage III and IV Melanoma Who Have Undergone Complete Resection in Austria

    Dec 1, 2024, 00:00

  • EE241 Fondaparinux: A Cost-Saving Alternative to Low-Molecular-Weight Heparins for Venous Thromboembolic Event Prevention/Treatment and Acute Coronary Syndrome Treatment

    Dec 1, 2024, 00:00

  • EE616 Cost of Illness Study of Inherited Retinal Diseases in the Netherlands in 2023

    Dec 1, 2024, 00:00

  • Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism [Editor's Choice]

    Dec 1, 2024, 00:00

  • HSD39 Beliefs and Behaviors of Healthcare Workers Towards Influenza Vaccination: A Systematic Review

    Dec 1, 2024, 00:00

  • CO130 Outcomes and Economic Effects of Digital Health Services: An Umbrella Review

    Dec 1, 2024, 00:00

  • HPR16 Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map

    Dec 1, 2024, 00:00

  • EE304 Economic Evaluation of Mailing Self-Sampling qFIT Kits to Non-Participants in Colorectal Cancer Screening in the Czech Republic

    Dec 1, 2024, 00:00

  • EPH36 Evaluation of the Impact of Herpes Zoster Vaccination in 18 to 49 Years Old German Patients With Immunosuppression on Public Health Measures

    Dec 1, 2024, 00:00

  • HSD9 Development of a Framework for a Networked Service Model for the Care of Adults With Rare Bone Conditions: Healthcare Professional Survey for X-Linked Hypophosphataemia (XLH)

    Dec 1, 2024, 00:00

  • EE672 Optimizing Costs and Sustainability for Gamma Knife Radiosurgery: A Cost and Breakeven Analysis at India's Largest Neurosurgery Centre

    Dec 1, 2024, 00:00

  • CO97 Characterizing the Burden and Unmet Need of Antibody-Mediated Rejection

    Dec 1, 2024, 00:00

  • CO66 A Systematic Review of Pharmacological Interventions for Hidradenitis Suppurativa: A Focus on Clinical Response, Quality of Life, and Safety

    Dec 1, 2024, 00:00

  • EE416 Cost-Effectiveness Analysis of Nirsevimab Prophylaxis for Prevention of Respiratory Syncytial Virus Disease Among Infants in South Korea

    Dec 1, 2024, 00:00

  • EE267 Cost Effectiveness and Budget Impact of the Recombinant Zoster Vaccine Among Older Adults in Singapore

    Dec 1, 2024, 00:00

  • HTA171 The Use and Influence of Real-World Evidence on French Health Technology Assessments

    Dec 1, 2024, 00:00

  • HTA24 What Key Areas of Clinical and Economic Uncertainty Have Scottish Medicines Consortium (SMC) Identified in Ultra-Orphan Initial Assessments to Date?

    Dec 1, 2024, 00:00

  • EPH26 New Pattern in Esophoria Incidence Identified by Linear Splines

    Dec 1, 2024, 00:00

  • HSD54 Epidemiology, Healthcare Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Claims Data Analysis in Germany From 2016 to 2021

    Dec 1, 2024, 00:00

  • HPR230 Overview of the Past and Future Development of Novel Antibiotics in Fran Is It Sufficient to Tackle Antimicrobial Resistance?

    Dec 1, 2024, 00:00

  • HPR243 Insights Into the Oncology and Allied Digital Health Landscape on the Island of Ireland: Implications for Policy and Practice

    Dec 1, 2024, 00:00

  • EPH150 Associations Between Co-Occurring Mental Disorders and Treatment Completion Among Women of Reproductive Age Admitted for Cannabis Dependen Evidence From the United States Treatment Episode Data Set

    Dec 1, 2024, 00:00

  • EPH176 Controlling RSV in Older Adults: Clinical Benefits of a Dutch Vaccination Program

    Dec 1, 2024, 00:00

  • HPR32 Assessing the Health Outcomes and Additional Budget Impact of PD-(L)1 Inhibitors in the Early Stages of Cancer Treatment in Greece

    Dec 1, 2024, 00:00

  • HTA182 Evaluating the Use, Performance, and Acceptability of Utility Measurement Approaches in Geographic Atrophy: A Severe Vision Disorder

    Dec 1, 2024, 00:00

  • EE563 Considerations for Health Economic Modelling in a Crowded Treatment Landscape: Lessons From Recent Models for Psoriasis, Psoriatic Arthritis, and Ulcerative Colitis

    Dec 1, 2024, 00:00

  • CO42 Comparison of Survival Outcomes for [177Lu]Lu-PSMA-617 vs Other Systemic Treatments in Post-Taxane Metastatic Castration-Resistant Prostate Cancer Setting: A Bayesian Network Meta-Analysis

    Dec 1, 2024, 00:00

  • EE675 Behavioral Considerations in Stated Preference Valuation of Human Life Metrics: Cost Vector Effects, Anchoring and Scope-Insensitivity

    Dec 1, 2024, 00:00

  • EE472 The Burden-of-Illness of Duchenne Muscular Dystrophy in Japan: A Socioeconomic Survey

    Dec 1, 2024, 00:00

  • EE834 The Economic Impact of the Use of Two Flowable Hemostatic Matrices in Spinal Surgery in Three European Countries

    Dec 1, 2024, 00:00

  • CO71 HTA Assessment of Quality of Survival Via Patient-Relevant Endpoints in Prostate Cancer

    Dec 1, 2024, 00:00

  • EE454 Budget Impact Analysis of Bimekizumab for the Treatment of Axial Spondyloarthritis (axSpA) in Greece

    Dec 1, 2024, 00:00

  • HPR31 Payer Preferences Around Manufacturer Provided Evidence and Engagements in the US

    Dec 1, 2024, 00:00

  • HPR112 Access to Coverage With Evidence Development Schemes for Medical Devices and Procedures in England, France, Germany, Spain, and the USA

    Dec 1, 2024, 00:00

  • EE797 Health Care Resource Use Associated With Respiratory Syncytial Virus Infection in Infants and Young Children in Germany: Evidence From the PAPI Study

    Dec 1, 2024, 00:00

  • EE372 Direct Health Care Costs Associated With Myasthenia Gravis (MG) in Hungary: A Claims Database Analysis

    Dec 1, 2024, 00:00

  • HTA141 Artificial Intelligen Is It a New Era in Payer Decision Making?

    Dec 1, 2024, 00:00

  • EE306 Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses

    Dec 1, 2024, 00:00

  • EPH220 Payer-Reported Patient Burden for Hematopoietic Cell Transplantation (HCT) in the United States

    Dec 1, 2024, 00:00

  • HTA33 Are Companies Ready for the New EU HTA, or Is It an Impossible Task?

    Dec 1, 2024, 00:00

  • EE347 Cost-Effectiveness and Value-Based Price of High-Dose Quadrivalent Influenza Vaccine Among Elderly Populations in Taiwan

    Dec 1, 2024, 00:00

  • EE556 Long-Term Outcomes in Hemophilia: The Impact of the Pettersson Score on Cost-Effectiveness Modelling

    Dec 1, 2024, 00:00

  • EE417 Quantifying the Value of Aztreonam-Avibactam in Treating Suspected Metallo-Beta-Lactamase Producing Enterobacterales Infections in Gree A STEDI Value Approach

    Dec 1, 2024, 00:00

  • HSD126 Evaluating the Degree of Coordination in Hypertension Medications Across Primary Healthcare Institutions, Secondary Hospitals, and Tertiary Hospitals in Shanghai, China

    Dec 1, 2024, 00:00

  • HTA129 Potential Impact of Joint Clinical Assessment (JCA) on Health Technology Assessment Timelines in Ireland

    Dec 1, 2024, 00:00

  • HPR64 Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review

    Dec 1, 2024, 00:00

  • HSD124 Application of Diagnosis-Related Group (DRG) in Measuring the Impact of Clinical Pathway on Resource Utilization for Patients Suspected With Acute Coronary Syndrome in the Emergency Department

    Dec 1, 2024, 00:00

  • EE708 Assessment of Direct Costs of Human Papillomavirus Related Diseases in Saudi Arabia

    Dec 1, 2024, 00:00

  • EPH261 Incidence and Prevalence of Non-Idiopathic Pulmonary Fibrosis (IPF) Progressive Fibrosing Interstitial Lung Disease (PF-ILD): A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • HSD63 Use of Resources and Cost in the Management of Gastrointestinal Bleeding Associated With Direct Oral Anticoagulants or Warfarin

    Dec 1, 2024, 00:00

  • EPH92 The Last of Fungus? Recent Developments in Fungal Infections in the German Hospital Setting

    Dec 1, 2024, 00:00

  • EE399 Economic Analysis of Digital Health Infrastructure: The Case of OneLondon's Impact on Time Efficiency and Safety in Healthcare Services

    Dec 1, 2024, 00:00

  • HSD89 Changes in Pneumococcal and Hexavalent Vaccination Schedule in Term-Born Infants: Potential Impact on Preterm Infants

    Dec 1, 2024, 00:00

  • HPR233 Impacts of National Volume-Based Procurement Policy on Prices of Non-Winning Drugs in China: An Interrupted Time Series

    Dec 1, 2024, 00:00

  • EE833 Economic Burden of Atherosclerotic Cardiovascular Disease in France in 2021: Results From the French Nationwide Claims Database (SNDS)

    Dec 1, 2024, 00:00

  • EE397 Differential Health-Economic Outcomes of Anti-Amyloid Treatment for Alzheimer's Disease Between Ethnoracial Groups in the United States

    Dec 1, 2024, 00:00

  • HTA143 A Review on the Role of Comparators in French Health Technology Assessments

    Dec 1, 2024, 00:00

  • EE312 Artificial Intelligence Prediction Tool for Prediabetes and Type 2 Diabetes Risk Stratification Using Computed Tomography Scans: An Early Economic Evaluation

    Dec 1, 2024, 00:00

  • HTA215 Targeted Review: Generalizability of Clinical Trial Evidence to the Patient Population in NICE Technology Appraisals

    Dec 1, 2024, 00:00

  • EE796 Cost Effectiveness of Selexipag Versus Placebo for Patients With Pulmonary Arterial Hypertension in Singapore

    Dec 1, 2024, 00:00

  • HPR26 Managed Entry Agreements to Mitigate Uncertainties and Reimbursement Challenges for Orphan Drugs: A Matrix to Determine Their Suitability

    Dec 1, 2024, 00:00

  • HSD104 Care Integration With Telemedicine for Remote Monitoring of Pressure Ulcers in Home Care Patients

    Dec 1, 2024, 00:00

  • EE608 Assessing the Economic Burden of Rare Disease Across Europe: A Health Economic Study of Financial and Quality of Life Impacts

    Dec 1, 2024, 00:00

  • HPR2 Addressing Legislative and Financial Hurdles in Rare Disease Medicines Accessibility: Insight From Czechia With a Focus on the Pediatric Population

    Dec 1, 2024, 00:00

  • HTA10 HTA Considerations for Large Language Models in Healthcare

    Dec 1, 2024, 00:00

  • EE786 QoL Data in CAR-T Cost-Effectiveness Analysis (CEA) in Fran What to Use?

    Dec 1, 2024, 00:00

  • HSD10 Reimbursement of Remote Health Services in Turkiye

    Dec 1, 2024, 00:00

  • EPH168 A Descriptive Epidemiological Study of Pediatric Sleep Medications in Japan: A Health Insurance Claims-Based Analysis

    Dec 1, 2024, 00:00

  • HPR79 The Turning Point of Substance Use Among Disadvantaged Young People in England: A Mediation Analysis

    Dec 1, 2024, 00:00

  • EE604 A Multi-State Model to Assess the Impact of Ruxolitinib in Extending Failure Free Survival and Life Expectancy in Patients With Steroid-Refractory Acute Graft vs Host Disease

    Dec 1, 2024, 00:00

  • HTA46 Difficulties of Choosing Proper Endpoints in Anti-Obesity Therapy Assessment

    Dec 1, 2024, 00:00

  • EE664 Cost-Effectiveness Analysis of IDP-126, a Topical Triple Therapy, for the Treatment of Acne Vulgaris From the Perspective of Canadian Public Payers

    Dec 1, 2024, 00:00

  • HPR137 Evaluating the Clinical and Socioeconomic Impact of Improved CKD Diagnosis and Adherence to Guideline-Directed Medical Therapy in Australia, Brazil, and China: An Impact CKD Analysis

    Dec 1, 2024, 00:00

  • Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study [Editor's Choice]

    Dec 1, 2024, 00:00

  • HTA181 Stakeholder Engagement in HTA: A Matter for Consensus?

    Dec 1, 2024, 00:00

  • HTA191 Main Restrictions Imposed by the National Commission for the Incorporation of Technologies in the Unified Health System (CONITEC) for the Incorporation of Medications in Brazil

    Dec 1, 2024, 00:00

  • EE803 Systematic Review of Healthcare Costs and Resource Utilization in Fibromyalgia in European Countries and the US

    Dec 1, 2024, 00:00

  • HTA100 How Do Abbreviated HTA Submissions Impact Reimbursement? A SMC Case Study

    Dec 1, 2024, 00:00

  • HPR155 Drug Repurposing: Policy Barriers to Using Existing Pharmaceuticals in New Indications: Results of a Systematic Literature Review

    Dec 1, 2024, 00:00

  • HPR148 Adopting CeSHarP M11 Guidelines for Oncology Protocol Digitalization: Findings and Action Recommendations

    Dec 1, 2024, 00:00

  • EE440 Cost-Effectiveness of Bioabsorbable Nasal Implant (Latera®) Versus Conservative Management for the Treatment of Nasal Airway Obstruction (NAO)

    Dec 1, 2024, 00:00

  • EPH53 The Indirect Costs Related to HPV-Attributable Cancer Mortality in European Countries; Years of Life Lost, and Productivity Costs

    Dec 1, 2024, 00:00

  • EE328 The Cost-Effectiveness of Germline BRCA Testing in Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers

    Dec 1, 2024, 00:00

  • EE414 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands

    Dec 1, 2024, 00:00

  • EE433 Cost Effectiveness (CE) Evidence Overview for Metformin and SGLT2is in Type 2 Diabetes (T2D) Patients With Cardiorenal Risk: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EE450 Economic Burden of People Living With HIV in China: An Analysis Based on Real-World Medical Database

    Dec 1, 2024, 00:00

  • EPH267 Estimating the Health Economic Benefits of Physical Activity for People With Limited Mobility

    Dec 1, 2024, 00:00

  • EE364 Cost-Effectiveness Analysis of Difelikefalin for the Treatment of Chronic Kidney Disease Associated-Pruritus in Spain

    Dec 1, 2024, 00:00

  • EPH203 Impact of Gender-Based Violence Cases in Bolívar, Colombia 2023

    Dec 1, 2024, 00:00

  • HTA101 Inequities in COPD Treatment Access Across Brazilian Municipalities: A Population-Based Analysis

    Dec 1, 2024, 00:00

  • EE564 Cost-Effectiveness of Alirocumab in Combination With High-Intensity Statin and Ezetimibe in Adults With Atherosclerotic Cardiovascular Disease (ASCVD) in Taiwan

    Dec 1, 2024, 00:00

  • EE566 Real-World Evidence of Multi-Gene Panel Sequencing Effectiveness and Cost-Effectiveness for Advanced Cancers: A Tumor-Agnostic Target Trial Emulation

    Dec 1, 2024, 00:00

  • EPH237 Vedolizumab Induced Cachexia: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

    Dec 1, 2024, 00:00

  • P8 Assessment of CO2 Equivalent Emissions in Effective Type 2 Diabetes Management: An Economic Modelling Study

    Dec 1, 2024, 00:00

  • HTA224 A Roadmap to the Use of Value of Information Analysis in Health Technology Assessment: An International Study of Barriers, Facilitators, and Potential Applications

    Dec 1, 2024, 00:00

  • P9 Recommended Standards for Managing and Reporting Missing Utility Data for Health Technology Appraisal

    Dec 1, 2024, 00:00

  • HPR247 Analysis of Oncology Medicine Distribution in Türkiye: A Focus on Indication, Molecule, and Generic Status

    Dec 1, 2024, 00:00

  • HSD18 Exploration of the Perception on Physical Activity and Its Correlation With Patients' Quality of Life at Vironas Health Center

    Dec 1, 2024, 00:00

  • EPH200 Administrative Frequency of Migraine and Clinical Characteristics in a Colombian Cohort From 2018 to 2022

    Dec 1, 2024, 00:00

  • EE591 Global Health Economic Burden of Angelman Syndrome: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • CO5 Healthcare Resource Utilization and Costs of Endometrial Cancer in France From 2016 to 2021 (MOONBEAM Study)

    Dec 1, 2024, 00:00

  • EE548 Cost-Effectiveness Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece

    Dec 1, 2024, 00:00

  • EE764 Cost Analysis of Rechargeable vs Non-Rechargeable Devices for Deep Brain Stimulation in Parkinson's Disease Treatment in Spain

    Dec 1, 2024, 00:00

  • HTA31 Insulin Analogs in Type 1 Diabetes Treatment: Is There Access After Unified Health System (SUS) Incorporation?

    Dec 1, 2024, 00:00

  • EE453 Clinical and Economic Benefits of Adopting Cladribine Tablets for the Treatment of Relapsing: Remitting Multiple Sclerosis in Public Health Service Institutions in Mexico

    Dec 1, 2024, 00:00

  • EE687 Cost-Effectiveness of Advanced Therapies Initiation in Patients With Rheumatoid Arthritis (RA) in Spain, Who Failed a Conventional Synthetic DMARD Versus a First Biological DMARD

    Dec 1, 2024, 00:00

  • EE799 COVID-19 Vaccination of Individuals Aged 65 Years and Over in Fran Clinical and Economic Impact of Vaccine Choice

    Dec 1, 2024, 00:00

  • HSD93 The Diagnosis and Management of Uncontrolled and Treatment-Resistant Hypertension: A Targeted Literature Review of Eight Countries Clinical Practice Guidelines

    Dec 1, 2024, 00:00

  • HPR235 The Impact of Dispensing and Non-Dispensing Practices on Outpatient Service Utilization and Expenses Under the Dual-Channel Policy in China

    Dec 1, 2024, 00:00

  • EPH41 Incremental Burden Attributable to Exposure to Socio-Environmental Factors on Patients With Lung Cancer in France

    Dec 1, 2024, 00:00

  • HPR190 Targeted Screening Interventions for Breast Cancer: Impact on Economic and Health Outcomes in Disadvantaged Populations

    Dec 1, 2024, 00:00

  • EE516 Non-QALY Benefits of Treatments of Alzheimer's Disease and Related Dementias

    Dec 1, 2024, 00:00

  • HSD14 Understanding Physicians Decision Making Processes When Treating Mild -to-Moderate Chronic Kidney Disease: A Qualitative Study

    Dec 1, 2024, 00:00

  • EE514 Budget Impact Model for Insulin Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the Treatment of Type 1 Diabetes Mellitus Based on the Inrange Study

    Dec 1, 2024, 00:00

  • EE357 Estimating Health State Utilities in LGMD 2E/R4, 2D/R3, and 2C/R5: Analysis of EQ-5D Baseline Data From the JOURNEY Natural History Study

    Dec 1, 2024, 00:00

  • EPH83 Public Health Impact of a Simplified Booster Vaccine Schedule Against Tick-Borne Encephalitis (TBE) in Austria: A Modeling Analysis

    Dec 1, 2024, 00:00

  • CO92 Comparative Efficacy and Safety of Faricimab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion (RVO): A Systematic Literature Review and Network Meta-Analysis

    Dec 1, 2024, 00:00

  • HSD50 Impact of Hospital Nurse Staffing on Direct Medical Cost and Patient Outcomes in China: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • CO51 Second-Line Pharmacological Interventions for Advanced Non-Small Cell Lung Cancer in MetEX14 Skipping Patients: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE517 Cell-Free DNA Epigenomic-Based Test Is Predicted to Be Cost-Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer

    Dec 1, 2024, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6 (current)
  • 7
  • 8
  • 9
  • 10
  • »